Company Overview and News
The Scotts Miracle-Gro Company (SMG - Free Report) recently said that consumer purchases of its lawn and garden products in May were at a record high of $565 million, leading to the near-full recovery of the decline reported by the company during the first seven months of the fiscal year. For the U.S. Consumer division, consumer purchases were nearly flat from 2017 levels on a year-to-date basis through Jun 10 with lawn fertilizer, growing media, grass seed and mulch witnessing positive growth.
WLK FTI.WI FMC CC SMG
This is the third month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $891.57.
GIS O.PRF WBA ENB OPRF JCI HSY ABBV MMM POL MO SMG IRET.PR DUKH GD IRET.PRC TRV IRET.PRB GPT.PRB MAIN BX CMI ENB RY BNS JNJ TROW GPT VZ ABBV MSFT WPC ADM PFE CLX PM PFBC SKT SCL CTL IRET OXLCM OXLCO TD ETN OXLCN BNS CM MSCA GPT.PRA INTC TD IBM IRET.PRCL RY TNTTF LYB O MSB DUK SNX OXLC IRM MSCA.CL EMRAF ORI PPL BMRC DLR CBL
MARYSVILLE, Ohio, June 12, 2018 (GLOBE NEWSWIRE) -- The Scotts Miracle-Gro Company (NYSE:SMG), the world’s leading marketer of branded consumer lawn and garden as well as hydroponic growing products, today announced that consumer purchases of its lawn and garden products were a record $565 million in May, resulting in the near full recovery of the decline reported through the first seven months of the fiscal year.
Last week, I told readers about the newest release of our annual report called “THE LIST” that identifies seven game-changing stocks for this year and beyond.
MARYSVILLE, Ohio, June 04, 2018 (GLOBE NEWSWIRE) -- The Scotts Miracle-Gro Company (NYSE:SMG), the world’s leading marketer of branded consumer lawn and garden as well as hydroponic growing products, today announced it has completed the acquisition of the assets of Sunlight Supply, Inc., enhancing the ability of SMG’s wholly-owned subsidiary, The Hawthorne Gardening Company, to drive improved performance while meeting the needs of the rapidly evolving hydroponic products marketplace.
The short position in marijuana-related equities has never been higher in terms of dollar value ($2.1 billion) or shares short (more than 200 million). The increase in shares means that in recent weeks, short-sellers have not only allowed the value of their positions to rise with the share prices, but they are also actively increasing the position size.
ACB GWPH SPG.PRJ INSY ACBFF CARA CRBP TSLA SPG APHQF GWP SMG
It’s hard to believe but the 2018 BIO International Convention is less than two weeks away! And even with the abundance of high-profile international companies that will converge on Boston for the 2018 BIO Convention, the work that is being done right in Boston’s backyard cannot be overstated. The New England region – consisting of Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island and Vermont – is one of the top regions for life science innovation and home to many companies working in agricultural innovation.
Maximus (MMS - Free Report) is a Zacks Rank #5 (Strong Sell) but it sports some solid style score grades. Let's take a look a the most recent quarter and the earnings estimates. Those will tell us why it is a Zacks Rank #5 (Strong Sell) and how it became the Bear Of The Day.
TAPOF MMS TPOYY BUD AIG.WS AVF AHBIF AIG TAP 8685 SMG
After nearly collapsing during the financial crisis in 2008, American International Group (AIG - Free Report) was once of the most high-profile beneficiaries of U.S. government intervention in the Troubled Asset Relief Program, commonly referred to as TARP.
BUD KMPR AIG.WS AVF KMPA AHBIF AIG AGN 8685 AKAM SMG
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to SMG / Scotts Miracle-Gro Company (The) on message board site Silicon Investor.
|THE SCOTTS CO. (SMG), Capable of Miracle Growth?|
as of ET